Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase 2 trial

Abstract

Trastuzumab, vinorelbine, HER-2 positive metastatic breast cancer, first-line chemotherapy